Terapi Dislipidemia untuk Mencegah Resiko Penyakit Jantung Koroner

  • Andriani Dearta Saragih Universitas Lampung
Keywords: penyakit jantung coroner, faktor resiko, dyslipidemia, terapi dislipidemia

Abstract

Penyakit jantung koroner (PJK) merupakan penyebab kematian utama di dunia.  Dislipidemia telah ditetapkan sebagai faktor resiko utama untuk terjadinya PJK disamping faktor resiko lainnya. Penelitian lain  yang  dilakukan  sebelumnya  memberikan  hasil  bahwa  dislipidemia  merupakan  faktor risiko tersering penyakit jantung koroner. Tujuan  literature  review  ini  dilakukan  untuk  membahas seputar  penanganan  yang  tepat  pada  dyslipidemia agar mengurangi resiko PJK. Sumber  yang  digunakan  dalam  penulisan  ini menggunakan artikel yang didapat dengan melakukan literature searching di PubMed NCBI. Literature searching dilakukan dengan menggunakan  kata  kunci  Dislipidemia,  Penyakit Jantung Koroner, risk  factor dan tatalaksana  yang  disaring dengan ketentuan publikasi tahun 2010-2020. Literature searching ini menghasilkan 1683 artikel yang  kemudian  dipilih 30 Artikel. umber  bacaan  yang  telah  dikumpulkan  kemudian  dianaliss dengan  metode  systematic  literature  review  yang  mencakup  aktivitas  pengumpulan,  evaluasi dan   pengemabangan   penelitian   dengan   fokus   topik   tertentu. Hasil   dari   literature review menunjukkan  bahwa terdapat hubungan antara kadar lipid dalam darah terhadap kejadian PJK. Pengelolaan pasien dislipidemia terdiri dari terapi non farmakologis dan farmakologis. Terapi non farmakologis meliputi perubahan gaya hidup, termasuk aktivitas fisik, terapi nutrisi medis, penurunan berat badan dan penghentian merokok. Sedangkan terapi farmakologis dengan memberikan obat anti lipid.

References

Alsheikh‐Ali AA, Abjourjaily HM, Stanek E. (2004) Increases in HDL‐cholesterol are the strongest predictors of risk reduction in lipid intervention trials. Circulation ;110(Suppl III):813.

Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini J, McPherson R. (2012). Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology.29(151-167).

Arthur SL. (2009). Dyslipidemia and Risk of Coronary Heart Disease: Role of Lifestyle Approaches for Its Management. American Journal of Lifestyle Medicine. 3(4):257-273.

Agrawal S, Zaritsky JJ, Fornoni A, Smoyer EW. (2018). Dyslipidemia in nephrotic syndrome: mechanism and treatment. Nature Rev. 14:57-70.

BIP Study Group. (2000). Secondary prevention by raising HDL cholesterol and reducing triglyceride levels in patients with coronary heart disease: the Bezafibrate Infarction (BIP) Study. Circulation. 102:21‐7.

Catapano LA, Graham I, DeBecker G, Wiklund O et al. (2016). ESC/EAS guidelines for the management of dyslipidemias. The task force for management of dyslipidemia of European Sociaety of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabillitation (EACPR). Atrherosclerosis. 1-64.

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. (2005). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine.350:1495‐504.

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. (2004). Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Ator vastatin Diabetes Study (CARDS): multicentre randomized placebo controlled trial. Lancet. 364:68596.

Ezetimibe—a new cholesterol‐lowering drug. (2004). Drugs and Therapeutics Bulletin. 42:65‐7.

Ferrari R, Aguiar C, Alegria E, Bonadonna CR et al. (2016). Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidemia. Eur Heart J. 18(C):C1-C12.

Grundy MS, Stone JN, Bailey LA, Beam C et al. (2018) AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/APhA/ASP C/NLA/PCNA. Guideline on management of blood cholesterol. JACC.

World Health Organization (WHO). (2018). Global Health Observatory (GHO) data. Available from: http://www.who.int/gho/ncd/risk_factors/cholesterol_ text/en/. Accessed.

Heart Protection Study Collaborative Group. (2002). Heart protection study of choleasterol lowering with simvastatin in20,536 high‐risk individuals: a randomized placebo‐controlled trial. Lancet. 360:7‐22.

Kiran M. (2010). Atherogenic Dyslipidemia: Cardiovascular Risk and Dietary Intervention. Lipids.45(10):907-914.

Soebardi S, Purnamasari D, Oemardi M, Soewondo P, Waspaji S, Soegondo S. (2009).Dyslipidemia in newly diagnosis diabetes mellitus. The Jakarta primary non-communicable disease risk factors surveillance. Acta Med Indones, 41(4): 186-190.

Sany RS. (2009). Dislipidemia Sebagai Faktor Risiko Utama Penyakit Jantung Koroner. Cermin Dunia Kedokteran. 36(3):181-184.

PERKI. Pedoman Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia (PERKI). (2004). Tata Laksana Sindroma Koroner Akut dengan ST Elevasi.Jakarta: PP PERKI

Sarah P, Alisson O, Robert C, Jemma CH, Michael RH, James O, Jane A, Collins, Rory C. (2012). Lipids and Lipoproteins and Risk of Different Vascular Events in The MRC/BHF Heart Protection Study. Circulation. 125(20):2469-2478.

Goldberg, Anne Carol. (2012). Dyslipidemia (Hyperlipidemia). Error! Hyperlink reference not valid..

Lin CF, Chang YH, Chien SC, Lin YH. (2018). Epidemiology of dyslipidemia in Asia Pacific region. Int J Geront 12:2-6.

Benjamin EJ, Blaha MJ, Chiuve SE et al. (2017). American Heart Association Statistic Committee and Stroke Statistic Subcommitte. Heart disease and stoke statistic 2017 update: a report from the American Heart Association. Circulation. 135:e146-603.

Eknoyan G, Lameire N. (2013). KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney International.

Jacobson AT, Ito KM, Maki CK et al. (2015). National Lipid Association (NLA) recommendation for patient-centered management of dyslidemia: part 1 (full report). J Clin Lipid. 9: 129-169

Chaudury B, Aggarwal A. (2018). Diabetic dyslipidemia: Current concepts in pathophysiology and management. J Clin Diag Res. 12(1): 6-9

Rader JD, Kheterpal AS. (2015). Lipoprotein physiology in: Dyslipidemias pathophysiology, evaluation and management. Garg A (ed), Humana Press:1-12.

Jellinger SP, Handelsman Y, Rosenblit DP, Bloomgarden TZ et al. (2017). American Association of Clinical Endocrinologist and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endoc Pract. 23(2): 1-67

Szabo ZN, Szodoray P, Kiss E. (2017). Dyslipidemia in systemic lupus erythematosus. Immunol Res.

Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. (2004). Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extendedrelease niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110:3512‐7.

Y L, Li SQ. (2014). Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of nine randomized controlled trials. Clinical Cardiology. 36(12):E41-8.

Vincent J, Carey et al. (2010). Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control. American Journal Cardiology. 106: 757-763.

Waspadji S, Suyono S, Sukarji K dan Kresmawan T. (2010). Obesitas Berdasarkan Tebal Lemak Bawah Kulit (TLBK) pada Penderita Hiperlipidemia. Pengkajian Status Gizi Studi Epidemiologi, FKUI, Jakarta.

Published
2020-10-29
How to Cite
Saragih, A. (2020). Terapi Dislipidemia untuk Mencegah Resiko Penyakit Jantung Koroner. Indonesian Journal of Nursing and Health Sciences, 1(1), 15-24. Retrieved from http://jurnal.globalhealthsciencegroup.com/index.php/IJNHS/article/view/223
Section
Articles